title: The PARADIGM of ARNI's: Assessing reasons for non-implementation in heart failure.
abstract: Several trials have targeted neutral endopeptidase to demonstrate benefits for patients with heart failure. In the PARADIGM-HF trial, a combination of sacubitril and valsartan was superior to enalapril in reducing the risk of death and of hospitalization for heart failure. In this editorial we apply the trial to heart failure population at large to estimate what proportion of patients might actually be treated in daily practice.
authors.affiliation: Department of Cardiology and Department of Research and Education, General Hospital Celje, Celje, Slovenia; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. Electronic address: mitja.lainscak@guest.arnes.si.
authors.forename: Mitja
authors.initials: M
authors.lastname: Lainscak
authors.affiliation: Monash University, Australia; University of Warwick, UK.
authors.forename: Andrew J S
authors.initials: AJ
authors.lastname: Coats
mesh_terms: D000613:Aminobutyrates / Q000627:therapeutic use; D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D004338:Drug Combinations; D004656:Enalapril / Q000627:therapeutic use; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D008297:Male; D008875:Middle Aged; D015260:Neprilysin / Q000037:antagonists & inhibitors*; D016032:Randomized Controlled Trials as Topic; D013777:Tetrazoles / Q000627:therapeutic use; D016896:Treatment Outcome; D000068756:Valsartan / Q000627:therapeutic use
chemical_list: D000613:Aminobutyrates; D057911:Angiotensin Receptor Antagonists; D001713:Biphenyl Compounds; D004338:Drug Combinations; D013777:Tetrazoles; D004656:Enalapril; D000068756:Valsartan; D015260:Neprilysin; C549068:sacubitril and valsartan sodium hydrate drug combination